The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Kennedy calls for a “moonshot” targeted on the role of the microbiome in cancer

Cancer Policy

FDA’s acting drug chief, acting vaccines chief, and chief of staff ousted in the wake of Makary departure

HHS rescinds vaccine panel charter citing “administrative error”

ACA Marketplace enrollment estimated to fall by 17%, KFF analysis finds

EPA moves to weaken limits of PFAS in drinking water

Supreme Court rejects pharma challenges against CMS drug price negotiating powers

DOJ alleges that Yale and UCLA discriminated based on race in medical school admissions

Clinical Roundup

Imfinzi regimen reduced early disease recurrence in non-muscle-invasive bladder cancer, phase III trial POTOMAC shows

Perioperative Imfinzi + neoadjuvant EV improved EFS and OS in muscle-invasive bladder cancer, phase III VOLGA trial shows

Intismeran cancer vaccine + Keytruda sustains 49% melanoma reduction after five years

Phase III trial of sacituzumab tirumotecan met primary endpoints in advanced or recurrent endometrial cancer

PSMAddition data show 58% lower risk of PSA progression with Pluvicto in metastatic hormone-sensitive prostate cancer

USC comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

In The Clinic

FDA clears fruit-flavored vapes, relaxes enforcement on black-market products with pending premarket applications
Critics say policies clear the way for major tobacco companies to enter fruit-flavored vape market

Trials & Tribulations
FreeTrials & Tribulations
Latest Issue
Read the latest issue
Read the latest issue
DOWNLOAD THE PDF
UPCOMING EVENTS
May 2026
29
2026 ASCO Annual Meeting
Jun 2026
25
MASCC/ISOO 2026 Annual Meeting
Sep 2026
18
NCCN 2026 Annual Congress: Hematologic Malignancies™️
View All Events

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account